Neogen Chemicals Ltd (NEOGEN)

Chemicals · Chemicals · NSE · Updated 17 September 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹2,301.95 ↑ 45.68% (1Y)

🎯 Key Takeaways

  • Neogen Chemicals is transitioning from a specialty chemicals manufacturer into a high-growth battery materials player, leveraging capacity expansion and government-aligned demand in India’s EV ecosystem. The company is in a strategic investment phase, with financial performance improving alongside execution of its Dahej plant reconstruction and new facility ramp-up.
  • Revenue grew 1.5% QoQ to ₹250 in Q1FY27.
  • ⚠️ Execution risk in scaling battery materials capacity and achieving ₹300 crore revenue target by FY27 amid execution delays or margin compression.
Market Cap
₹6,303
P/E Ratio
173.2
P/B Ratio
7.72
ROE
4.4%
ROCE
6.2%
Debt/Equity
1.63
Div Yield
0.04%
Promoter
53.0%

📖 The Story

Neogen Chemicals is transitioning from a specialty chemicals manufacturer into a high-growth battery materials player, leveraging capacity expansion and government-aligned demand in India’s EV ecosystem. The company is in a strategic investment phase, with financial performance improving alongside execution of its Dahej plant reconstruction and new facility ramp-up. While profitability remains volatile due to CAPEX intensity, recent margin expansion and revenue growth signal progress toward scalable, sustainable earnings.

📰 What's Happening

In Q1 FY27, Neogen reported consolidated revenue of ₹250.3 crore (+34% YoY) and PAT of ₹17.1 crore (+62% YoY), driven by strong volume growth in battery chemicals and operational recovery. Management highlighted near-complete reconstruction of the Dahej plant and progress on a new battery materials facility targeting startup in FY27. A Board-approved ₹600 crore QIP aims to reduce debt and fund expansion, with ₹1,800 crore CAPEX planned, of which ₹1,300 crore already spent. Battery materials revenue reached ₹19 crore (+280% YoY) and is expected to hit ₹300 crore by FY27. Management emphasized full utilization of electrolyte capacity by FY29 and debt reduction to INR 1,000-1,500 crore peak. Shareholding shows rising institutional interest, with FII and DII stakes increasing sequentially over recent quarters.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricSep 2025Dec 2025Mar 2026Jun 2026
Revenue209220247250
Operating Profit23253640
OPM %10.8%11.4%14.7%16.0%
Net Profit341117
EPS₹1.28₹1.40₹4.32₹6.29

Revenue has grown steadily from ₹209 crore (Sep 2025) to ₹250 crore (Jun 2026), with net profit expanding from ₹3 crore to ₹17 crore over the same period, reflecting improved operational leverage. EBITDA margins rose to 16% in Q1 FY27 from 10.8% in Sep 2025, supported by higher gross profit (₹30 crore, +194% YoY) and efficient cost management despite input cost pressures. The company is investing heavily in CAPEX (₹1,800 crore planned), with ₹1,300 crore already deployed, primarily in battery materials infrastructure. While working capital cycles remain elevated in the battery segment, management targets normalization to 90 days by FY27, indicating improving cash flow discipline amid scaling operations.

🔮 Management Outlook & What's Next

Management projects FY27 as a pivotal year for execution, targeting ₹300 crore revenue from battery chemicals and full utilization of electrolyte capacity by FY29. CAPEX of ₹1,800 crore is being deployed to scale high-margin segments, with plans for international approvals and US tax credit eligibility under non-FEOC status. The company aims to reduce net debt to INR 1,000-1,500 crore peak and improve working capital efficiency. Long-term growth is anchored in India’s projected 200+ GWh battery demand by 2032 and strategic positioning in the PLI scheme for lithium-based products.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital26262626
Reserves751763773790
Borrowings5345971,1321,330
Total Liabilities1,5501,7472,3022,902
Fixed Assets519403425475
Investments2401010
Total Assets1,5501,7472,3022,902

The balance sheet shows a leveraged but improving capital structure. Total borrowings rose to ₹1,330 crore by Mar 2026 from ₹1,132 crore in the prior year, reflecting active CAPEX financing, but equity remains stable at ₹26 crore with reserves growing to ₹790 crore. The ₹600 crore QIP is intended to reduce debt burden and strengthen financial flexibility. Despite rising liabilities, asset growth (₹2,902 crore in Mar 2026) outpaces liability increases, driven by investments in plant infrastructure and intangible assets. Management’s capital allocation prioritizes growth reinvestment over immediate deleveraging, with debt reduction contingent on operational execution and cash flow generation.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2026
Operating-231
Investing-410
Financing+642
Net Cash Flow-0

👥 Shareholding Pattern

CategoryQ3FY26Q4FY26Q1FY27
Promoters51.2%51.2%53.0%
FII4.6%4.5%4.1%
DII22.0%22.6%19.6%
Public15.3%15.1%16.4%
# Shareholders47,88454,33261,988

Institutional interest is rising, with FII holding increasing from 4.46% (Q4FY26) to 4.11% (Q1FY27) and DII from 22.64% to 19.6% over the same period, despite a slight dip in absolute values. Promoter holding remains stable at ~53%, with no significant dilution or sale signals. The number of shareholders has grown from 47,884 (Q3FY26) to 61,988 (Q1FY27), indicating retail broadening. No insider selling has been reported recently; the only insider transaction was a minor share gift within family, which is non-dilutive and immaterial to governance or control.

⚖️ Peer Comparison — Chemicals

Company MCap (₹ Cr) P/E ROCE ROE D/E
PIDILITIND 1.57 L Cr 59.4 33.4% 24.7% 0.01
SRF 73,659 34.1 15.6% 15.4% 0.36
LINDEINDIA 51,983 95.2 17.5% 12.8% 0.00
FLUOROCHEM 49,864 81.5 9.6% 7.7% 0.34
NAVINFLUOR 41,888 53.0 22.2% 19.9% 0.31
GODREJIND 38,200 32.5 9.2% 19.8% 4.57
HSCL 32,947 40.9 20.7% 17.1% 0.16
DEEPAKNTR 21,689 27.7 15.3% 13.4% 0.26
AETHER 21,288 90.3 13.8% 10.6% 0.08
CASTROLIND 18,675 17.6 76.2% 55.9% 0.00

⚠️ Risk Factors

1. Execution risk in scaling battery materials capacity and achieving ₹300 crore revenue target by FY27 amid execution delays or margin compression. 2. High CAPEX intensity may strain cash flows if revenue growth slows or demand forecasts materialize later than anticipated. 3. Working capital cycle in the battery segment remains elevated, potentially pressuring near-term liquidity. 4. Dependence on government incentives and PLI scheme benefits exposes the company to policy volatility. While margins have improved, sustained profitability in the battery segment is not yet proven at scale.

📋 Recent Filings

🧠 Analyst's Read

Neogen Chemicals is executing a clear strategic pivot toward battery materials, supported by strong top-line growth, improving margins, and targeted CAPEX deployment. The next few quarters will be critical to validate execution against ambitious revenue and capacity targets. Investors should monitor progress on plant commissioning, debt reduction, and working capital normalization in the battery segment as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NEOGEN files new disclosures

Track NEOGEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track NEOGEN — Free

Free account · 2 AI queries/day